Participant flow14

How many started, completed or left each group, period by period.

1 to 14 of 14

Period	Milestone	Group	Participants
Overall Study	STARTED	Selumetinib 75 mg BD + RAI	155
Overall Study	STARTED	Placebo + RAI	78
Overall Study	Intention to Treat (ITT) Analysis Set	Selumetinib 75 mg BD + RAI	155
Overall Study	Intention to Treat (ITT) Analysis Set	Placebo + RAI	78
Overall Study	Safety Analysis Set	Selumetinib 75 mg BD + RAI	154
Overall Study	Safety Analysis Set	Placebo + RAI	77
Overall Study	BRAF/NRAS Mutation Positive Analysis Set	Selumetinib 75 mg BD + RAI	91
Overall Study	BRAF/NRAS Mutation Positive Analysis Set	Placebo + RAI	51
Overall Study	Ongoing at Primary Analysis Data Cut-off	Selumetinib 75 mg BD + RAI	134
Overall Study	Ongoing at Primary Analysis Data Cut-off	Placebo + RAI	71
Overall Study	COMPLETED	Selumetinib 75 mg BD + RAI	133
Overall Study	COMPLETED	Placebo + RAI	69
Overall Study	NOT COMPLETED	Selumetinib 75 mg BD + RAI	22
Overall Study	NOT COMPLETED	Placebo + RAI	9

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01843062/flow